Improving survival for patients with GIST

Average life expectancy had been no better than 18 months for people diagnosed with advanced gastrointestinal stromal tumors, or GISTs. The outlook changed dramatically in 2001 with the arrival...

For rare tumors, a far-reaching trial of immunotherapy

The first federally funded clinical trial of immunotherapy for rare cancers launched this week under the auspices of SWOG, the research consortium headquartered at the OHSU Knight Cancer...